Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Vera Therapeutics, Inc. (VERA)

35.89 +0.90 (+2.57%)
At close: 4:00:00 PM EDT
36.00 +0.11 (+0.31%)
After hours: 6:01:52 PM EDT
Trade VERA on Coinbase
Chart Range Bar
Loading chart for VERA
  • Previous Close 34.99
  • Open 34.69
  • Bid 22.14 x 100
  • Ask 38.91 x 200
  • Day's Range 34.69 - 36.41
  • 52 Week Range 21.96 - 56.05
  • Volume 1,184,417
  • Avg. Volume 2,107,569
  • Market Cap (intraday) 2.586B
  • Beta (5Y Monthly) 0.95
  • PE Ratio (TTM) --
  • EPS (TTM) -5.87
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 77.14

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

veratx.com

361

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VERA
29.13%
S&P 500 (^GSPC)
12.75%

1-Year Return

VERA
63.88%
S&P 500 (^GSPC)
18.71%

3-Year Return

VERA
93.58%
S&P 500 (^GSPC)
70.93%

5-Year Return

VERA
39.11%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -121.03M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

-120M
-100M
-80M
-60M
-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

34.00
77.14 Average
35.89 Current
100.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/17/2026
Analyst Wedbush
Rating Action Reiterates
Rating Neutral
Price Action Maintains
Price Target 34 -> 34

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    2.47B

  • Enterprise Value

    2.05B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    6.06

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -46.76%

  • Return on Equity (ttm)

    -91.75%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -401.9M

  • Diluted EPS (ttm)

    -5.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    499.16M

  • Total Debt/Equity (mrq)

    18.86%

  • Levered Free Cash Flow (ttm)

    -212.95M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

35.89 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: